Phase II trial of chemoradiotherapy using weekly gemcitabine (GEM) in patients (pts) with locally advanced pancreatic cancer (PC). Final results
Chigusa Morizane(Tokyo National Hospital), Hiroshi Ikeda, Yoriko Takezako(Tokyo National Hospital), Minako Sumi(Tokyo Metropolitan Geriatric Hospital), Hideki Ueno(National Defense Medical College), Takuji Okusaka(National Cancer Centre Japan), M. Ikeda, Yoshikazu Kagami(Tokyo National Hospital)
Cited by 0
Related Papers
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer
|International Journal of Clinical Oncology|2017|2.5k
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer
|International Journal of Clinical Oncology|2019|2k
Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer
|NEJM Evidence|2022|1.1k
Trans-ancestry mutational landscape of hepatocellular carcinoma genomes
|Nature Genetics|2014|780
Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan
|British Journal of Cancer|2010|749